2.
    发明专利
    未知

    公开(公告)号:SE7500423L

    公开(公告)日:1975-07-17

    申请号:SE7500423

    申请日:1975-01-15

    Applicant: HOECHST AG

    Abstract: 1480432 Polyethers HOECHST AG 13 Jan 1975 [16 Jan 1974] 1339/75 Heading C2C [Also in Division C5] Novel polyethers having the formula wherein R is (C 1 -C 4 )alkyl, x and z are 1, 2 or 3, are prepared by the reaction of an ether of the formula ROÀ(CH 2 CHO) x H or a mixture thereof, with ethylene oxide and propylene oxide at an elevated temperature and pressure in the presence of an alkaline catalyst, by either (a) reacting an excess of the ether in a first reaction step with propylene oxide and, after removal of the excess starting ether, reacting the product obtained in a second reaction step with ethylene oxide, or (b) reacting ethylene oxide, propylene oxide and an excess of the ether, relative to the oxide mixture, and distilling the mixture under reduced pressure to obtain a sump product consisting of the final product. The novel compounds can be used as brake fluids.

    INSULIN DERIVATIVES MODIFIED IN THE B30 POSITION, PROCESSES FOR THEIR PREPARATION

    公开(公告)号:NZ209620A

    公开(公告)日:1988-03-30

    申请号:NZ20962084

    申请日:1984-09-21

    Applicant: HOECHST AG

    Abstract: 1. Claims for the Contracting States : BE CH DE FR GB IT LI LU NL SE A medicament having a delayed action for the treatment of diabetes mellitus, comprising at least one insulin derivative of the formula I see diagramm : EP0137361,P16,F1 in which R**1 denotes H or H-Phe R**30 represents the radical of a neutral, genetically codable L-aminoacid whose OH group, where present, can be free or protected by a physiologically acceptable group, and R**31 denotes a physiologically acceptable neutral group blocking the carboxyl group, with the exception of des-B30 human insulin Leu**B30 -NH2 and des-B30 human insulin Gly**B30 -NH2 and des-B30 human insulin Phe**B30 -NH2 and a pharmaceutically acceptable carrier. 1. Claims for the Contracting State : AT A process for the preparation of a medicament having a delayed action for the treatment of diabetes mellitus, which comprises bringing into a suitable dosage form at least one insulin derivative of the formula I see diagramm : EP0137361,P17,F1 in which R**1 denotes H or H-Phe R**30 represents the radical of a neutral, genetically codable L-aminoacid whose OH group, where present, can be free or protected by a physiologically acceptable group, and R**31 denotes a physiologically acceptable neutral group blocking the carboxyl group, with the exception of des-B30 human insulin Leu**B30 -NH2 and des-B30 human insulin Gly**B30 -NH, and des-B30 human insulin Phe**B30 -NH2 Phe**B30 -NH2 and a pharmaceutically acceptable carrier.

    9.
    发明专利
    未知

    公开(公告)号:DK16682A

    公开(公告)日:1982-07-18

    申请号:DK16682

    申请日:1982-01-15

    Applicant: HOECHST AG

    Abstract: What is disclosed is a method for making human insulin or modified human insulin from pig insulin or modified pig insulin by reacting the pig insulin starting material at a pH below its isoelectric point with an excess of a threonine ester in the presence of trypsin or a trypsin-like enzyme.

    POLYETHER MIXTURES
    10.
    发明专利

    公开(公告)号:ZA755B

    公开(公告)日:1976-01-28

    申请号:ZA755

    申请日:1975-01-02

    Applicant: HOECHST AG

    Abstract: 1480432 Polyethers HOECHST AG 13 Jan 1975 [16 Jan 1974] 1339/75 Heading C2C [Also in Division C5] Novel polyethers having the formula wherein R is (C 1 -C 4 )alkyl, x and z are 1, 2 or 3, are prepared by the reaction of an ether of the formula ROÀ(CH 2 CHO) x H or a mixture thereof, with ethylene oxide and propylene oxide at an elevated temperature and pressure in the presence of an alkaline catalyst, by either (a) reacting an excess of the ether in a first reaction step with propylene oxide and, after removal of the excess starting ether, reacting the product obtained in a second reaction step with ethylene oxide, or (b) reacting ethylene oxide, propylene oxide and an excess of the ether, relative to the oxide mixture, and distilling the mixture under reduced pressure to obtain a sump product consisting of the final product. The novel compounds can be used as brake fluids.

Patent Agency Ranking